Xianwei Chen

Oct 23, 2024 | cell.com | Yue Qin |Qi Cui |Guihua Sun |Jianfei Chao |Cheng Wang |Xianwei Chen | +12 more

Oct 12, 2023 | frontiersin.org | Jeffrey Jones |Xianwei Chen

Introduction Alzheimer's disease (AD) remains a leading cause of dementia and poses a heavy burden on aging populations worldwide (Long and Holtzman, 2019). Amyloid-targeting antibodies have recently gained accelerated (aducanumab) and full approval (lecanemab) by the Food and Drug Administration, ushering in a new era of AD therapeutics targeting neuronal pathology (Shi et al., 2022).